Oxigene Gets Development Funds For Zybrestat In Collaboration With Symphony
This article was originally published in The Pink Sheet Daily
Executive Summary
Unique deal structure creates new company to develop Zybrestat for ophthalmology and second oncologic while giving Oxigene option for reacquisition.
You may also be interested in...
Royalty Flush: Why Monetizing Tomorrow's Revenue Stream Today Could Catch on in a Big Way
Biotechs remain voracious consumers of capital, but tapping the equity markets is often prohibitively dilutive. Royalty financing can provide lower-cost-of-capital funding while putting a price on assets the market often ignores. This cash can also allow biotechs to hold onto R&D projects longer, eventually pushing up the price of licensing deals. But although royalty financiers are eager, they are limited in the amount of risk they are willing to take; new players in the business though may nevertheless increase competition and drive prices up.
Oxigene Reports Positive Data For Zybrestat In Platinum-Resistant Ovarian Cancer
Novel vascular disrupting agent is also in studies for anaplastic thyroid cancer and macular degeneration.
FDA Agrees To Pivotal Protocol For Oxigene’s Vascular Disrupting Agent Zybrestat
Oxigene has begun enrollment in the Phase II/III trial to test combretastatin-A4 in the orphan setting of anaplastic thyroid cancer.